A crucial milestone in achieving increased patient access to biological therapies

The European Commission today organised its 4th annual workshop on biosimilar medicines, bringing together patients, specialist nurses, doctors, pharmacists, payers, academics, public authorities, and industry across Europe.

This workshop is a key milestone in stakeholder dialogue to advance the potential of biosimilar medicines and the role they play in increasing patient access to biological therapies in Europe. The event brought together patients, specialist nurses, doctors, pharmacists, payers, academics, public authorities, press and industry to share experiences with biosimilar medicines across Europe.The European biosimilar medicines stakeholder community welcomes the 4th annual workshop on biosimilar medicines, organised today by the European Commission Directorate General for the Internal Market, Industry, Entrepreneurship and SMEs (DG GROW) on access to biosimilar medicines in Europe. This workshop is a key milestone in stakeholder dialogue to advance the potential of biosimilar medicines and the role they play in increasing patient access to biological therapies in Europe. The event brought together patients, specialist nurses, doctors, pharmacists, payers, academics, public authorities, press and industry to share experiences with biosimilar medicines across Europe.The event has provided a great platform for information sharing on topics such as the role biosimilar medicines will play in cancer care, the importance of sustainable procurement practices for a healthy, competitive, off patent biologics and biosimilar medicines landscape and of education in improving stakeholder literacy on biosimilar medicines.

Find out more in the multi-stakeholder press release